Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 7/2014

01-07-2014 | Inflammatory Bowel Disease (S Hanauer, Section Editor)

Environmental Triggers for IBD

Authors: Aoibhlinn O’Toole, Joshua Korzenik

Published in: Current Gastroenterology Reports | Issue 7/2014

Login to get access

Abstract

The fundamental elucidation of how environmental influences provoke the initiation of disease as well as flares of inflammatory bowel disease (IBD) remains incomplete. The current understanding of these diseases suggests that ulcerative colitis (UC) and Crohn’s disease (CD) result from poorly defined interactions between genetic and environmental factors which culminate in the pathologic effects and clinical manifestations of these diseases. The genetic variant appears not sufficient itself to lead to the development of the clinical disease, but likely must combine with the environmental factors. The intestinal microbiome is pivotal to IBD development. A greater understanding of the contribution of these factors to dysbiosis is critical, and we aspire to restoring a healthy microbiome to treat flares and ideally prevent the development of IBD and its complications. This article aims to place the environmental influences in the context of their potential contribution to the development of the pathophysiology of IBD.
Literature
1.
Kabi A et al. Digesting the genetics of inflammatory bowel disease: insights from studies of autophagy risk genes. Inflamm Bowel Dis. 2012;18(4):782–92.PubMedCentralPubMedCrossRef
2.
3.
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627–40.PubMedCrossRef
4.
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–34.PubMedCrossRef
5.
6.
7.
Mahurkar S et al. Common variants in NOD2 and IL23R are not associated with inflammatory bowel disease in Indians. J Gastroenterol Hepatol. 2011;26(4):694–9.PubMedCrossRef
8.
9.
Forbes A, Kalantzis T. Crohn’s disease: the cold chain hypothesis. Int J Color Dis. 2006;21(5):399–401.CrossRef
10.
11.
Dominguez-Bello MG et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971–5.PubMedCentralPubMedCrossRef
12.
Bager P et al. Cesarean section and offspring’s risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012;18(5):857–62.PubMedCrossRef
13.
Sonntag B et al. Preterm birth but not mode of delivery is associated with an increased risk of developing inflammatory bowel disease later in life. Inflamm Bowel Dis. 2007;13(11):1385–90.PubMedCrossRef
14.
Cabrera-Rubio R et al. The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. Am J Clin Nutr. 2012;96(3):544–51.PubMedCrossRef
15.
16.
Spooren CE et al. Review article: the association of diet with onset and relapse in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(10):1172–87.PubMedCrossRef
17.
Castiglione F et al. Risk factors for inflammatory bowel diseases according to the “hygiene hypothesis”: a case-control, multi-centre, prospective study in Southern Italy. J Crohn’s Colitis. 2012;6(3):324–9.CrossRef
18.
Roberts CL et al. Translocation of Crohn’s disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut. 2010;59(10):1331–9.PubMedCentralPubMedCrossRef
19.
20.
Jakobsen C et al. Environmental factors and risk of developing paediatric inflammatory bowel disease—a population based study 2007–2009. J Crohn’s Colitis. 2013;7(1):79–88.CrossRef
21.
Ananthakrishnan AN et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology. 2013;145(5):970–7.PubMedCrossRef
22.
Tsiountsioura M, et al Detailed assessment of nutritional status and eating patterns in children with gastrointestinal diseases attending an outpatients clinic and contemporary healthy controls. Eur J Clin Nutr. 2014;68(6):700–6.
23.
Burisch J, et al Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe—an ECCO-EpiCom study. J Crohns Colitis. 2014;8(7):607–16.
24.
Palmblad J, Gyllenhammar H. Effect of dietary lipids on immunity and inflammation. Review article. APMIS. 1988;96(7):571–83.PubMedCrossRef
25.
Costea I et al. Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric Crohn’s disease. Gastroenterology. 2014;146(4):929–31.PubMedCrossRef
26.
Laing B, Han DY, Ferguson LR. Candidate genes involved in beneficial or adverse responses to commonly eaten brassica vegetables in a New Zealand Crohn’s disease cohort. Nutrient. 2013;5(12):5046–64.CrossRef
27.
Vind I et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101(6):1274–82.PubMedCrossRef
28.
Benchimol EI et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58(11):1490–7.PubMedCrossRef
29.
30.
Wang TT et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem. 2010;285(4):2227–31.PubMedCentralPubMedCrossRef
31.
Ooi JH et al. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr. 2013;143(10):1679–86.PubMedCrossRef
32.
Baumgart M et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J. 2007;1(5):403–18.PubMedCrossRef
33.
Barnich N et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest. 2007;117(6):1566–74.PubMedCentralPubMedCrossRef
34.
Martinez-Medina M et al. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014;63(1):116–24.PubMedCrossRef
35.
36.
Gilat T et al. Childhood factors in ulcerative colitis and Crohn’s disease. An international cooperative study. Scand J Gastroenterol. 1987;22(8):1009–24.PubMedCrossRef
37.
38.
Hansen TS et al. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohn’s Colitis. 2011;5(6):577–84.CrossRef
39.
Virta L et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease—a nationwide, register-based Finnish case–control study. Am J Epidemiol. 2012;175(8):775–84.PubMedCrossRef
40.
Marchant A et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol. 1999;163(4):2249–55.PubMed
41.
Ennis FA et al. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination. J Infect Dis. 2002;185(11):1657–9.PubMedCrossRef
42.
Villumsen M et al. Risk of inflammatory bowel disease following Bacille Calmette-Guerin and smallpox vaccination: a population-based Danish case-cohort study. Inflamm Bowel Dis. 2013;19(8):1717–24.PubMed
43.
Ng SC et al. Role of genetic and environmental factors in British twins with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(4):725–36.PubMedCrossRef
44.
Van Kruiningen HJ, Freda BJ. A clustering of Crohn’s disease in Mankato, Minnesota. Inflamm Bowel Dis. 2001;7(1):27–33.PubMedCrossRef
45.
Pierce ES, Borowitz SM, Naser SA. The Broad Street pump revisited: dairy farms and an ongoing outbreak of inflammatory bowel disease in Forest, Virginia. Gut Pathog. 2011;3(1):20.PubMedCentralPubMedCrossRef
46.
Pierce ES. Free-ranging Rocky Mountain bighorn sheep and an outbreak of inflammatory bowel disease along the Clark Fork River in Plains, Montana. Virulence. 2012;3(6):546–50.PubMedCentralPubMedCrossRef
47.
Masclee GM et al. Is Clostridium difficile associated with relapse of inflammatory bowel disease? Results from a retrospective and prospective cohort study in the Netherlands. Inflamm Bowel Dis. 2013;19(10):2125–31.PubMedCrossRef
48.
Ananthakrishnan AN et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 2012;156(5):350–9.PubMedCentralPubMedCrossRef
49.
Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol Ther. 2009;30(6):517–31.PubMedCrossRef
50.
51.
Etminan M et al. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149(2):216–20.PubMedCrossRef
52.
Looijer-van Langen M et al. Estrogen receptor-beta signaling modulates epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G621–6.PubMedCrossRef
53.
54.
55.
Higuchi LM et al. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107(9):1399–406.PubMedCentralPubMedCrossRef
56.
57.
Verschuere S et al. Cigarette smoke and the terminal ileum: increased autophagy in murine follicle-associated epithelium and Peyer’s patches. Histochem Cell Biol. 2012;137(3):293–301.PubMedCrossRef
58.
59.
Khalili H et al. Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses’ Health Study cohorts. BMJ. 2013;347:f6633.PubMedCentralPubMedCrossRef
60.
Lange T, Dimitrov S, Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci. 2010;1193:48–59.PubMedCrossRef
61.
Uthgenannt D et al. Effects of sleep on the production of cytokines in humans. Psychosom Med. 1995;57(2):97–104.PubMedCrossRef
62.
Swanson GR, Burgess HJ, Keshavarzian A. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare? Expert Rev Clin Immunol. 2011;7(1):29–36.PubMedCentralPubMedCrossRef
63.
Ranjbaran Z et al. The relevance of sleep abnormalities to chronic inflammatory conditions. Inflamm Res. 2007;56(2):51–7.PubMedCrossRef
64.
65.
Ananthakrishnan AN et al. Sleep disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis. Clin Gastroenterol Hepatol. 2013;11(8):965–71.PubMedCrossRef
66.
Ali T et al. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013;19(11):2440–3.PubMedCrossRef
67.
Mawdsley JE, Rampton DS. The role of psychological stress in inflammatory bowel disease. Neuroimmunomodulation. 2006;13(5–6):327–36.PubMedCrossRef
68.
Rampton DS. The influence of stress on the development and severity of immune-mediated diseases. J Rheumatol Suppl. 2011;88:43–7.PubMedCrossRef
69.
Ananthakrishnan AN et al. Association between depressive symptoms and incidence of Crohn’s disease and ulcerative colitis: results from the Nurses’ Health Study. Clin Gastroenterol Hepatol. 2013;11(1):57–62.PubMedCentralPubMedCrossRef
70.
Langhorst J et al. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. Inflamm Bowel Dis. 2013;19(11):2380–6.PubMedCrossRef
71.
Vanuytsel T, et al Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63(8):1293–9.
72.
Martin Sanchez F, et al, Exposome informatics: considerations for the design of future biomedical research information systems. J Am Med Inform Assoc. 2014;21(3):386–90.
73.
Tringe SG, Rubin EM. Metagenomics: DNA sequencing of environmental samples. Nat Rev Genet. 2005;6(11):805–14.PubMedCrossRef
74.
75.
Nes AA, et al Web-based, self-management enhancing interventions with e-diaries and personalized feedback for persons with chronic illness: a tale of three studies. Patient Educ Couns. 2013;93(3):451–8.
Metadata
Title
Environmental Triggers for IBD
Authors
Aoibhlinn O’Toole
Joshua Korzenik
Publication date
01-07-2014
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 7/2014
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-014-0396-y

Other articles of this Issue 7/2014

Current Gastroenterology Reports 7/2014 Go to the issue

Inflammatory Bowel Disease (S Hanauer, Section Editor)

Managing Clostridium difficile in Inflammatory Bowel Disease (IBD)

Nutrition and Obesity (SA McClave, Section Editor)

The Pharmacologic Treatment of Short Bowel Syndrome: New Tricks and Novel Agents

Pediatric Gastroenterology (S Orenstein, Section Editor)

Childhood Chronic Nausea: Is It Just a Queasy Stomach?

Nutrition and Obesity (SA McClave, Section Editor)

Bugs or Drugs: Are Probiotics Safe for Use in the Critically Ill?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits